Where does Enveric Biosciences Canada Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Enveric Biosciences Canada Inc. ranks #12,912 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Enveric Biosciences Canada Inc. hold?

Enveric Biosciences Canada Inc. holds 23 US utility patents granted between 2023 and 2025, spanning 11 technology areas.

What is Enveric Biosciences Canada Inc.'s Innovation Score?

Enveric Biosciences Canada Inc. has an Innovation Score of 55.9 out of 100 (top 6% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Enveric Biosciences Canada Inc. focus on?

Enveric Biosciences Canada Inc.'s top technology area is C07D (Heterocyclic Compounds) with 23 patents, ranking #383 of 3,165 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Enveric Biosciences Canada Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Enveric Biosciences Canada Inc..

What does claim depth mean for Enveric Biosciences Canada Inc.'s patents?

Enveric Biosciences Canada Inc.'s patents average 22.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Enveric Biosciences Canada Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Enveric Biosciences Canada Inc.

USPTO PatentsView assignee record - 23 granted patents across 11 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Enveric ranks #12,912 of 49,997 tracked US assignees by granted-patent volume, with 23 patents across 11 technology areas.

#12,912
of 49,997 US assignees by volume: Top 6%
by Innovation Score (55.9/100): 22.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R12912 · Foreign Corporation #12,912 · 23 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 23 grants
MID-PACK #12,912/49,997
PHOTO-FINISH Edscha Engineering
CPC-FOCUS C07D · 11 areas
INNOV-PAR 55.9/100
CLAIMS-DENSE 22.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Edscha Engineering GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Enveric’s 55.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.0 pts (20%) Velocity 20.0 pts (36%) Breadth 11.7 pts (21%) Claim depth 13.2 pts (24%)

Qualcomm Incorporated · highest

85
Enveric Biosciences… · this assignee

56
3D Lighting… · lowest

7

What this shows Enveric's Innovation Score is 55.9/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Enveric?

Each dot is one of Enveric’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Enveric’s own 22.0 claims/patent is ABOVE the 14.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Enveric vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Enveric's grants concentrate

Enveric Biosciences Canada Inc. is a focused PatentsView assignee: 11 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (12 grants) versus a trough of 5 in 2023. By volume, Enveric sits between Edscha Engineering GmbH and Federal-mogul Valvetrain GMBH.

Enveric's three-year grant acceleration

Enveric Biosciences Canada Inc. shows 17 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Edscha Engineering

23
Elite Material (Z…

23
Elobau & KG

23
Enovate Medical

23
Ergon Asphalt & E…

23
Excelsior Medical

23
Faltec

23
Federal-mogul Val…

23
Enveric Bioscienc… ◀

23

What this shows Enveric holds 23 patents at rank #12,913, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Enveric

By rank, the assignees closest to #12,913 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Enveric's primary technology class.

Enveric's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Enveric Biosciences Canada Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	5	21.7%
2024	12	52.2%
2025partial year	6	26.1%

Which technologies does Enveric Biosciences Canada Inc. patent most?

C07D - Heterocyclic Compounds 23

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 19

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 11

C12Y - Enzymes 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 11

C07K - Peptides 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Enveric Biosciences Canada Inc.'s patent record in context - here's where to go next.

Enveric Biosciences Canada Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #12,912 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Enveric Biosciences Canada Inc. against Edscha Engineering GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 55.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.